Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial

GSK announced that analysis of the MAGRITi trial, a phase III trial of its MAGE-A3 cancer immunotherapeuticii in NSCLC patients, showed that the trial did not meet its first or second co-primary endpoint as it did not significantly extend DFSiii when compared to placebo in either the overall MAGE-A3 positive population or in those MAGE-A3-positive patients who did not receive chemotherapy.
Source: GSK news - Category: Pharmaceuticals Source Type: news